About: The Miller Fisher syndrome (MFS) is classified as a variant of the Guillain–Barré syndrome (GBS), accounting for 5‐25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence of the neurologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both central and peripheral nervous system, has been described. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical parameters of a case with a typical clinical presentation of MFS after being tested positive for SARS‐CoV‐2 infection.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Miller Fisher syndrome (MFS) is classified as a variant of the Guillain–Barré syndrome (GBS), accounting for 5‐25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence of the neurologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both central and peripheral nervous system, has been described. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical parameters of a case with a typical clinical presentation of MFS after being tested positive for SARS‐CoV‐2 infection. Goto Sponge NotDistinct Permalink

An Entity of Type : fabio:Abstract, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	abstract
value	The Miller Fisher syndrome (MFS) is classified as a variant of the Guillain–Barré syndrome (GBS), accounting for 5‐25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence of the neurologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both central and peripheral nervous system, has been described. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical parameters of a case with a typical clinical presentation of MFS after being tested positive for SARS‐CoV‐2 infection.
subject	Zoonoses Autoimmune diseases Viral respiratory tract infections COVID-19 Acting Writing Book terminology Cytomegalovirus-associated diseases Occupational safety and health RTT RTTNEURO Word processors Syndromes affecting the nervous system Medical triads Peripheral nervous system disorders Narratology
part of	Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
is abstract of	Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
is hasSource of	covid:ann/target/e3951c130e6c5b6fab55cbc81e9dfeaaa2819804 covid:ann/target/a26c0181e3b1a6b14d8359ba464f73f832be1b93 covid:ann/target/8928b69446ef3bccc8de82e4ff3a605ec84f4b44 covid:ann/target/9661b51487eb270b4b5e50c1ac2bed3ee702ffbd covid:ann/target/24d8aef465e5804db6bca363a9cd43b5bfe3a75c covid:ann/target/75a94f57e9d1d1e006f2c1513c509341ab3e93db covid:ann/target/cc60f7ed6be56384d7cb2aad02f5433b8918c8e4 covid:ann/target/c61c756954229824589ecacc2d5978b4fd2b109a covid:ann/target/dfa3cd6a2030fe4e6c020c9932917e9576ba46d0 covid:ann/target/dc7cb67c77f9ed96c432ee09eeadf52d7074fc4e covid:ann/target/4480251c5cb826bd9c542da7f05b47da2efe7880 covid:ann/target/69a4d48435b0b4fbe55348f4660c49725a3e0fda covid:ann/target/dab947ddb1563fcbf013678772d6c944b020e30b covid:ann/target/9d5b07a8c5a6a1753439a3d544a779280bdd136f covid:ann/target/a7fb9570996dfff3f6e046fbf90835c3c044e20f covid:ann/target/80c4983f004c7922ad0b7bbbcf6726c329a9c8c8

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software